Chapter 3.3. Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease

  1. Peter G. Gibson1,
  2. Michael Abramson2,
  3. Richard Wood-Baker3,
  4. Jimmy Volmink4,
  5. Michael Hensley5 and
  6. Ulrich Costabel6
  1. Christine Jenkins

Published Online: 25 OCT 2007

DOI: 10.1002/9780470987377.ch20

Evidence-based Respiratory Medicine

Evidence-based Respiratory Medicine

How to Cite

Jenkins, C. (2005) Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease, in Evidence-based Respiratory Medicine (eds P. G. Gibson, M. Abramson, R. Wood-Baker, J. Volmink, M. Hensley and U. Costabel), Blackwell Publishing Ltd, Oxford, UK. doi: 10.1002/9780470987377.ch20

Editor Information

  1. 1

    John Hunter Hospital, Newcastle, New South Wales, Australia

  2. 2

    Monash University, Central & Eastern Clinical School, The Alfred, Melbourne, Victoria, Australia

  3. 3

    University of Tasmania, Hobart, Tasmania, Australia

  4. 4

    University of Cape Town, Cape Town, South Africa

  5. 5

    University of Newcastle, Newcastle, New South Wales, Australia

  6. 6

    Ruhrlandklinik, Essen, Germany

Publication History

  1. Published Online: 25 OCT 2007
  2. Published Print: 22 NOV 2005

ISBN Information

Print ISBN: 9780727916051

Online ISBN: 9780470987377



  • inhaled corticosteroids;
  • chronic obstructive pulmonary disease therapy;
  • clinical trials;
  • lung function;
  • inflammation


This chapter contains sections titled:

  • Inhaled corticosteroids in chronic obstructive pulmonary disease (COPD)

  • Early clinical trials with inhaled corticosteroids assessing lung function in patients with COPD

  • Clinical trials examining the effect of corticosteroids on decline in FEV1 in COPD

  • Larger long-term studies of the effect of ICS on FEV1 decline

  • Other clinically important outcomes for COPD studies : more than lung function

  • Side-effects

  • ICS withdrawal

  • Mortality in COPD and the effect of ICS